Molecular pathway analysis of Amyotrophic Lateral Sclerosis by genome-wide expression profiling of human blood and skin fibroblasts.

Completed

• Conditions: Amyotrophic Lateral Sclerosis (ALS); motor neuron disease; 10029317

• Registration Number: NL-OMON31437
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 2000

Inclusion Criteria

- Age > 18 years
- Diagnosis of ALS or other ALS-mimic disorder
- No cognitive impairement

Exclusion Criteria

- Diagnosis unknown

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Expression profiles will be observed specific for ALS and/or disease<br /><br>progression. Findings can be translated into diagnostic tools. The genetic<br /><br>study will identify DNA variants related to ALS specific expression profiles<br /><br>leading to new insights into the genetic basis of disease susceptibility and<br /><br>progression.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>nvt</p><br>